ZGNX - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Zogenix, Inc.

First Quarter 2021 Financial Results Conference Call. [Operator Instructions] As a reminder this conference is being recorded today Thursday, May 6, 2021. I would now like to turn the conference over to Brian Ritchie of LifeSci Advisors. Please go ahead.

Brian Ritchie

thank for and afternoon. us operator, you, you joining all this Thank me Chief are today's Officer, With call Executive on Dr. Stephen Sagrolikar; Farr; and Ashish Chief Financial Chief Officer, Michael Commercial Officer, Smith. update a quarter first March XX, providing Zogenix for ended news afternoon, financial results issued a This business and XXXX. announcing the release today of note Securities the Please call Litigation certain the under Reform discussed information covered that Private Safe the Act. on is Harbor provision forward-looking during that call, management statements. this making We caution listeners will Zogenix be those business. stated due from implied results by uncertainties statements materially Actual could forward-looking or to associated these differ with and risks the company's These the the Zogenix's company's in are XX-K annual forward-looking and including press filings, Form statements filings. the in qualified cautionary statements subsequent SEC today report by release issued on contained and also only contains is this that of date call as the broadcast, information May XXXX. accurate live time-sensitive conference X, of This to any or conference Zogenix or circumstances undertakes the statements events call. date after revise no of this to reflect obligation update forward-looking

Steve. call Now I'd like to the to over turn

Stephen Farr

the Thank exciting ongoing notice you, things another with Germany, updates been shortly. I'm has Despite pandemic to Brian, Gen which for on what X. to pleased afternoon. by today the and you on and of progress productive in provide operational Europe United quarter good are and be Ashish commercial based continue in will describe brought happen States to challenges as the here well, very

by physicians continuing more on tracks. new gaining based both in physicians ability base government We are to never see wishing positive and example, We're with travel we and With and amount field the see dose, and increased very commercial by other the healthcare an for a and encouraged with payers. existing by beneficial to of experience professionals. meet historic adoption impact physicians dosing and and effective that increase dialogue teams and the going in growth prescribing steady patients patients the more

this to call are our progressing aspects Europe. will positive we details business. the activities how further forward in have on for to our looking commercial impact US over and other Ashish the are our the turn and in of a As launches on result, now I'll

Ashish, over to you?

Ashish Sagrolikar

US Thank very the and update strong you details XXXX, share desire first community we the achieved of in $XX.X with net of This TensorFlow continued the were with million of to net Dravet product execution our million I'm in on $X in team's you, launch quarter strong and pleased within and in to FINTEPLA the we the gaining sales momentum the initiate to continue In map. Europe. significant sales. the reflects Steve. US you FINTEPLA planned are Germany. treatment million in early $XX.X performance center

with ability related the And We the that most to weather have of related year. been impacted our really US, moment, sustain COVID beginning in headwinds. significant in country the despite pleased the this disruptions of

new. participate XX% REMS did the the program, expect and COVID of FINTEPLA That in broadening prescribing In in QX, number the long professionals step adoption, the experience of of trial program, XXX plus prescribing were increase treating And not noted, By and clinical positive end center We to the in these begin certified a program our access the as of remains prescribers more than More interest interest approx. impacts prescribing FINTEPLA. continue or higher FINTEPLA. that US physicians the expanded hcps in gain robust. into to physicians is already in Steve our reflecting of enrolling initial diminish. indicator patients. majority with to as are healthcare of term REMS growth use

increase over were end brought in the just a referred XXX. prescribed and patients total since About of first prescribed XX% the quarter, US REMS XXX of the to FINTEPLA, which During This the XXXX. patients number is new

saw from month January increasing we March. through consistently new Importantly, to of month rate reference patient a

see patients. patients growth the than consisted grew More was expect access the XX% patients extremely than in And from FINTEPLA. transitioning and our this new participants reimbursed this continued growth XXX trend open the level therapy the throughout number final of in receiving XX% We commercial more year. by by when were QX the expanded of and driven by FINTEPLA to to By pleased US are to rest who March of program. to the XX, quarter studies

be the XX% published as continue than of to FINTEPLA. had in with access parity By pleased a FINTEPLA, the for to live formal payer policy label coverage with on other U.S as of extremely more cover We end covering can QX, per areas.

and of rest of medical authorization rare their profits, it necessity covered prevalence covering the the to plans, syndrome prior rare population. through in due With

in patients the we are and for verification we some the Additionally, of disorders, also re Pierce's severe Dravet reinforcing the of seizure been in have for than successfully belief during value. completed syndrome mid-teens. Dravet other the epilepsy. percentage for January, Since of in REMS By enrolled written all But patients of diagnosed prescriptions the syndrome. QX, coverage in the for patients launch, was process written the rare end seeing the US other prescribed program of majority therapeutic month with FINTEPLA FINTEPLA prescriptions

patterns approximately per FINTEPLA treatment by similar of what X.X expanded is The month the six. of the patients dose the patients per seizure increased Current by reaching and to relative patients to with the daily dose we also approximately milligrams program, their that saw reduction, kilogram We fourth reach in weight, titrating the physician average effective to XX% effective confidence see following indicate prescribing tolerance. day. calculation in dose of remainder access namely,

studies. very still our high continues in launch, retention it Although early clinical that our program, and expanded rate is be experience to very consistent XX% our with access in the

us physicians, this staff. patients facing year, trend in into an environment second of and Transitioning As continue for interact are seizure. with who families been have to FINTEPLA and with US believe the positive able considering half treatment the to customer easier rates increase, schedule interactions now our to We more making ease restrictions person it Europe. improve of SCPs vaccination in the with to will and teams their

us across Our launch are progressing mid their label first access enrolled European a as further until in launch, than to controlled finalized. axis version In the think of market process to with global This commercial Germany, in discussed now that year. by pharma medicine access the expanded program Israel. allow. has for being forward FINTEPLA of to in we need and negotiations the patients expand eligible European this or earlier Kingdom, not FINTEPLA some open make look AEU reflecting reimbursement be major strong as studies we be February the in France, patients negotiations other yet launched clinicians such are in to more patients XXX progression patients. and France are June. well. to first entered well. temporary of in of available established. FINTEPLA interest European the In I program, is physicians more to We further the But includes this under regulations local and become FINTEPLA. program. supporting patients through this hcps program Italy reimbursement an we FINTEPLA our world countries expect These very few therapy, FINTEPLA had France for we to prescribed program extension In this after agreement in weeks QX, patients where XX are the Access In progressing a United completed therapy to transitioning new been initiate also now x under in end approximately participating will Germany availability to are reimbursement where into parts In operation April, the in AEU

file strong regulatory and now and pass lab, growth Europe partners covered very reimbursement our the due countries. additional that and patients partnerships reimbursement with to programs in prepare other benefiting United from in with working continued now pandemic States, European in momentum, with in documents To us countries. impacts the approval the conclude, treatment more are in anticipate of to new pleased are we and addition and we and we worst We approvals We and hope, our Israel. FINTEPLA receive are pricing and of progress for

it will Now, turn Steve? I Steve, to back

Stephen Farr

great for progress. Ashish, the you, Thank

to LGS in of including opportunity a syndrome for FINTEPLA a [indiscernible] larger I'd with second FINTEPLA you like that indication pipeline, array update as Japan. on our LGS Next, as well

disease. priorities supplemental for in XXXX Europe FINTEPLA and a milestones quarter. community Our to remains MMA quarter Both epilepsies discussions reinforce submission advocacy in to Therefore, in the XXXX. us and manage, still severe followed one are the fourth desperately in LTS United and NDA third patients challenging most for of high fighting by treatments patient excited be track for planned we're a LGS significant States the this of for red LGS need new many on the

notably quintuplets patient's part the new sees pre any are data SNDA the our demonstrating confirm clinical these to phase The complement excited podium to treatment. death of analyses epilepsy. new a to meet FDA LGS option control significantly meeting novel this final of trial be for data other drop believe that frequency advisory the [ph] for or We risk positive and LGS not in seizure generalized clinical These is self-regulate engaged recent phase could meeting. a results non-seizure FINTEPLA the a impact reinforce at the cognitions. other combined on patient to we treatment and and parallel, for preparations, important relative electronic about as we These report showed the ability treatment position from align and in to tonic-clonic for for findings patients. AAN for of LGS LGS with a each in seizure a of primary candidates FINTEPLA mechanism submission goal that three, primary well frequency, and discussions a panels presentation XXXX earlier As emotions agreements action on have three factor potentially behavior, therapies approved who In structure. that earliest sudden we to control intend it were LTS clinicians with unexpected quarter from during pivotal seizures reduced data

for may the ways they FINTEPLA tonic-clonic high for stated While likely number They their treatment of a who risk also patients. experience may generalized algorithm at conditions they all refractory seizure. that be try who patients and of this indicate other in in of would seizures place the trade LGS

our FINTEPLA responses our Separately, this the in Now be comparison randomized the into in to patients to for syndrome the Dravet patients. enable pre Japan. XX plan Japanese will remain which last on requested for We JNDA turning submission study, later NDA LGS year. track

from phase the So abroad a [ph] three study multinational trial. data XXX

also CDKLX trial in great or three of phase preparing making LGS, in In addition progress CDD. we FINTEPLA our disorder, to are planning the around deficiency

compelling study showed of We year Dr. reminder, initiated patients discuss from quarter unexpected Medical patients data at a during As Anda last the with year. NYU the Vinski FDA in CD plan several into with enrollment protocol the beginning CBD. of second CES Langone of the half the to investigator Center this study final

can position the total XXXX. for As property addition see, to listed patents significant you objectives, for the FINTEPLA's from these FINTEPLA was -- attempt appendix by last for growth complement intellectual patents with [ph] orange of quarter to XXXX we book. the plans FINTEPLA. in further strengthened our brings have us ranging To further This

Now, I'd MTXXXX. like to discuss

our continued deficiency thymidine excited a data TKXd. investigational with report or patient our as stage demonstrating population no in late Our benefit we therapy mortality Leveraging to therapy bring both this TKXd. sets, forward to two kinase and approved in for morbidity I'm treatments. progress

on the remain patients in We results is initial and estimated of making unmet death. and with will indication high of this and the studies childhood or respiratory we our late reference often disease, failure a parallel pursuing our been represent Based are the FDA The required thereafter. approval in MTXXXX for encompassing disease possible. and Europe, onset better the track All are half to planned. as as we In soon infant all Non-offset identify European less group recently of indication all patients minority represents population, milestones, work, of TKXd a clear impatience, drug as an and we of with pursue advancing submissions an with has activities to will a patients available which study. those on-site onset of the may our XX% largest with to to patients file. of for in in only group discussions developmental loss first submit to our TKXd. progress a goal an for NDA rapidly to an patients, characterize the and range an shortly on of NDA development XXXX, And Untreated pursue need. patients recognized BMA early

of TKXd of is TKXd mitochondrial critical testing. many diagnosed. a setting is by In definitively the disease, with suspicion easily genetic significantly under diagnosed diseases, As the

of improve panels, access characterize To activities we and on therefore programs for for are continue medical conclude, caregivers, the to to research urgency three Zogenix and this engaged MTXXXX and of to clinical areas see impact very test, low important drive to in genetic families. programs present disease exciting ramped the of to been for productive and partnerships to and commercial understand up indications. a scientific education and this new disease patients, testing get and We to FINTEPLA testing work, advance quarter has record TKXd and as chapter a genetic development market ensure on non-cost testing and priority is awareness

let the that, me the review. hand over Mike call financial to for with So

Michael Smith

with or of quarter $X.X in decrease quarter please million our was the that, and and a a product sheet, were in our $XX.X cash, business now turn you March for balance XX, year. the Germany, release This jury result quarter March totaling strong million, a XXXX, can other record million a which million recorded year I'll fourth the financial United QX X.X XXXX. of the in call XXXX. open We product in increase recognize $XX.X ended the Total for for products, quarter first over million million XXXX. XXXX million XX% XXXX. forthcoming launch was in for review. compares Net up now our Steve the ended the This LGS FINTEPLA approximately the $X Net million, million for R&D as million share. first ended to a in XX% XX.X preparations quarter million. the in cash questions? marketable $X.X an as SG&A States, With increase afternoon, collaboration recognize the for to The in equivalents the compared the compared increase XX.X in to for total quarter as in sales first loss We operator We first of XX start quarter period of with corresponding XX $XX first we good for million, Today, ago. to results total United expenses an quarter March for revenue of announcing everyone. ended Nippon the share revenue the net quarter million first press with exclusive the to of FINTEPLA XX where $X.XX of with reported million ended fourth related driven compared which million $XX.X XXXX, ended $X States related in in first per to securities and three compared FINTEPLA to related the per of the the quarter in to first within XXXX, distribution, the $X.X the a expenses investment total Thanks, primarily Europe and March months in issued increase XXXX. March to Europe, loss commercial I'll for or countries sales XXXX was in by session. $XX.X XX.X in launch the $XXX Tableau coming line Operator, Japan. the and of of in XX $X.X $X.X the the of and the syndrome the Shinyaku other Q&A FINTEPLA, of

Operator

ahead. Paul Stifel. question go Please first in line Our from Instructions] of Mateus comes [Operator

Paul Mateus

appreciate it. for Hey, always thanks taking much the questions so always as

couple. a So

side, in commercial had wanes. encouraging more face that person of as your On you LGS. then to Is virtual been month past there any the interaction any hear in versus it way pandemic percent as what And you've face you of can a over separately the meetings that person it's are and seeing to or byproduct on the have increase in volumes two? quantify

more like the do just that Or much. Just SNDA single know wondering, administrative? was stage serve need I little can as kind you Steve, feel of this pre of basis so Thanks for a a you reaffirmation Is could to bit? set this ahead get pilot. a meeting, still you the you pivotal

Stephen Farr

Thank you, Paul.

first. Ashish, commercial take the Paul's address me to you ready Let question. get LGS And if question could

So take as much regarding advantage and we clarity to eventual on the meeting, pre sponsors, have other as review NDA our doesn't And really hopefully that SNDA the track. was be to this the absolute time submission FDA, programs there's a can development an in is standard all NDA. as the part remains think of ensure we to like nor of front for it ensure of I

past, good as around would of the FDA and got we've those So we agreements package end interaction had non-clinical the mentioned, with what in year the the be. at last package clinical and really the really on

more more and for standard, get on what proposed be and previous it So reaffirmation And it's our it's us, mentioned, agreements. the our this I them us is as opportunity feedback for confirming gives also both for would administrative label initial helpful to of LGS. and

there to Over it's in upsides So going the a the lot and are to forward Ashish. not of timeline. going impact of meeting,

Ashish Sagrolikar

Yep. Hi, Paul.

been you weeks. in terms on or managers trend loves still of than industry to the last go four there two in primarily the terms the been obviously account certain person we in in more pharmaceutical I'll in. country, recent And interaction a of physicians, year, out come pockets In give the to key their able a of in our thirds XX%, and call have field are allowing has qualitative quantifying are

limits, off appointments. the opening stay will because we we start but that still up they getting can areas those hoping are So are

got I this towards we starting March. the thing add been end have we would is of other doing in The

our are in doing did programs in are attended person in some was in person, places person. services we webinar, huge just We which demo doing a we in

you continue But going the that to know, of of patients increasing, almost expecting of positive country. of seeing every come trend coming these and as kind are COVID more officers as trend allowing So towards in some part that to visiting because things and in vaccinations all the patients in the telemedicine the that conditions, offices we're offices these with the the are risk. the of is continuing and we want with chronic because

more So to up come that one.

Paul Mateus

great. to the quarter? what finally just mind in And gross net just you quickly was Okay, quantifying would

Stephen Farr

I Mike. the Yeah, take that. It's can in It's teens.

So been it's you is full there started, to a it earlier because But a that low eventually think we lower be bit we're year, going know, commercial the we think since has in which patient over publication. population the I be once up get will will currently we post launch in than than eventually in coming little XXs. in the will

Paul Mateus

right. All Thanks.

Operator

line Marc SVB in Our with Goodman Please of next go comes question ahead. Leerink.

Marc Goodman

Just the are a one, just that of first therapy? average the sense can on question. give us price who the patients That's

is, was and give week first you of relative of, time. color said label you May, last of lastly, get mentioned about you what XX%. trying just, I April's things kind think that then know, off to to how of can going just us And how question Second you been are a sense

it Thank you. This quarter, what quarter? last was

Stephen Farr

that a then Thanks, going average quarter. price, color take we're as bit could well. Ashish, on you Mark. also patients provide sort on, these I'll question on nondairy a And seeing know, this and of you of if what's

month increase of very simply, a month over she response, nice question. what previous seen We've I the said Mark, just it QX. previous patients think in rates in in So follows

[ph] trend quarter have other this we're mass part And are words, more in of the patients as seeing to we in early that in well. REMS in coming January. So the

just result Ashish about hand So I that to earlier. Ashish. over talked a And of I'll think is with that, what

Ashish Sagrolikar

the of we now having continues five. same, Yeah, the the more the towards we terms are who five, year. thanks. more therapy, now Hi, point patients point getting is and price, are on are average would around be first Mark, But say because it in in average again, that dose I to

translate you it's around if annualized, that into So XXX,XXX.

rate forward overall driveway. So that launch. not patients the it will the going is be terms than in on indications of other really the since will That's be the

from is analysis out. have from if we population that clarify So comment, of I said haven't separated the did number has and think now mouth. kind to we And we just really you when number is that starting come means looks that what the launch the everything recall And entire that my to earlier, within.

sharing are it. So that's why we

Marc Goodman

So the pretty been consistent. comment is it's that

XX%? guess launched You're Is saying? I saying what And that's you're since true. at

besides up, which one There is LGF Just is patients other LGF. everything follow

Ashish Sagrolikar

and classified been but epilepsies confirm refractory has it of as that sentenced you epilepsy of I can the imagine, rare the in it's majority and of that see, is the Yeah, that can terms you the LGS. all is as

you of So some and other refractory up and see thirds of epilepsy. them the LGS to two

Operator

America. ahead. line next go Our Tazeen with Please Ahmad in question of comes of Bank

Tazeen Ahmad

afternoon. get some FDA know, other accelerated good where expectations standard whether for some to you to prepare questions. approval. application, therapeutic Thank path you and have on an some, as In granted there have Steve likely review. you other Hi, that file on think quarter so has CNS taking to to to the might filings been much of a get and recent set is areas, thoughts, And examples been your my this wanted accelerated you the for congratulations LGS

thoughts to then And wanted get your I that. have follow a I up. So on

Stephen Farr

Appreciate the question.

patient, medical FDA stand hard unmet we clear, from importantly drugs the determine forward and well. where that observing. we treat, LGS interesting, the a moment, going to a syndrome And fact think, to for Yes, as are but review the loud already seven hear still us. the the FDA or to that not advocacy only upon at I the very rushing an we're there's based And approved supplemental groups heard put that's despite allow what composition, we've need. have best we priority NDA. eight is to our urgent for also

of with best a approved move argument you we review, the review. it's hasn't said is might justify forward downside So forward knows. priority. know, priority that, interest drugs we our that the best but it's make unless push ultimate FDA we XX that with a everyone's to Having devastating to months, which to that to be move try would already will And but can to and me, that them in standard decision you the know, feel do

Tazeen Ahmad

for for Okay, how to FINTEPLA. comfortable the Is paperwork relates if not a like it writing as formulary maybe that's formulary, need great. color important feel it color at Then point to understand on even how kind Thanks the them. doctors provide And the to to the launch, can for case you feel limiting on on exactly be, know, for factor this like, some out. they that Ashish what doctors they is a it's not know, rate you of fill script

Ashish Sagrolikar

going we really submissions conversation the is then factor patients. in be this every it not And is their had, was, to diseases for all. limiting as hasn't you best When and what it know, particular come interactions particular a have Yes, space, rare up. at in that prescribe

other to office version as there have as diseases. managing into for thing geared in And the to really is we entire really the and rare do the process. is staff process well the The staff support experienced extension, up this which the add physician there is

the go becomes that and had within a entire success. patients process to but product And at, through that comfortable prepared so weeks, remarks, point far, get And good the will the therapy. look physicians in the have this really four to that reference also for we two my be

Tazeen Ahmad

for Okay, the I onboarding patient, and already tried know, you up patients squeeze last profile percent the them know, if that could a have that you are, the question, dialects? what of are in of

Ashish Sagrolikar

would you I a to anti-epileptic to we four know, quintuplet you they what X have can an as we that therapy. have of And to up that something them haven't seen is added with else, tried gets imagine, XX. input average as drugs case, share you out that on We can broken the on. seen most have And is as different on worst very are around

And the can start the okay, they is other then if do or one patient looking of at So the any even to stabilized, added terms product will they overall once patient product of on in else will is products, CBD that. the burden. get FINTEPLA what of reducing the

Tazeen Ahmad

it. you got so Thank much. Okay,

Operator

Raymond in Our Brill line of go next question James. with Danielle Please comes ahead.

Unidentified Analyst

is can percent patients understand and because the quickly, thank in looks for like in quarter REMS. Danielle, you REMS patients are This Asking us of upcoming the you enrolled reimbursed taking that the on Neal you help XXX drugs? question. last Very enrolled what have

quarter, patients This XXX queue? a northern that new that Thank and does drug imply have you both one in REMS XX pays draw patients received on you.

Stephen Farr

addressed to explain drugs? of want prescribe you and the then do between Ashish that difference and the REMS funnel the in top the

Ashish Sagrolikar

Yes.

weeks. at just XXX the if the when the at of of absolute numbers at on And and the and XXX the reimbursed here therapy So four at we it have QX, and patient's at takes the look top enrolled into in XXX the terms on patients plus you the you had program. add funnel end because the around reimburse of going the at around top when around you to XXX at recall, of to funnel, of look patients funnel, end want then the getting therapy, you who

just let's four but So say it's weeks.

that as into that and Hope So program, come you're helps come lag there. the in going to to therapy. end REMS therapy then reimburse the the understand receiving the they have question patients on as

Unidentified Analyst

you very much. Thank

Operator

to comes go ahead. with please question of line Blair, next Tim William Our Lugo the

Unidentified Analyst

taking the is this for for Laughlin thanks Tim, questions. Hey, on

the change about should was we I in think wondering how of productivity So sales reps. that

rest get certified and we've in? that digital I in realm world As compared interactions or that a been have And population? you have, of within with may, few two their person the only that their they eligible second of so them more patients sort most patients expanding have on before of they many more question, into of one they the patients of how or to the sort each. potentially virtual trialing if therapy, doctors Or

Ashish Sagrolikar

with question I'll first. second the start

but patients the imagine, leaders, are a program, can prescribers and can prescribing, their they physicians of of said the my prepared not you are but have when part physicians if physicians thought in And more for terms as So in patience, who that you this, expanded in multiple can also been And almost writing our not trial, And are you we most is, access are who remarks, a we I not lot. seeing a are who center. of you where we have are from coming majority, XX% lot our of thought your have, tell have leader community clinical they have I we if physicians. on prescriptions. what community written seeing community only are many,

comfortable going be I think question. with again, the because of of because But Or or for else setting, talk first places it's kind we of both they or them any your the launched about into have it not not to families seen feeling where I that because because change COVID. that. all may leads have within they because something the the COVID. don't written patients what into their even offered of may the patients, trying a they of of a to haven't healthcare and all some COVID are So that who challenges the will benchmark is, have most their and restrictions

to down in only brand best environment anti-epileptic class, can XX% back what XX%. offer will physicians them, to to the every COVID patients. every prescriptions entire where go went new their I saw and back And and we think go the the of patience up have to one educate almost one who the to I for the to that the doing they make sure we product two to the RF go be is

Unidentified Analyst

for color. the Thanks thanks. Awesome,

Operator

next go Our Guggenheim line to ahead. comes Yatin of with Partners, question Suneja the please

Yatin Suneja

you for star guys, I my by had question. one press know that. Didn’t was thank for taking pressing I sorry Hey, to one about so

couple questions a Okay, me. for

So In Europe? terms Can total us European of component you sale? the there was number in how What is to number that's any the much was one. tell the it? sale,

got mention did because to that added and trying were I think cadence in forward, going a drug just is or there sense in dynamic question QX. EAP patients second the you that new trying know, QX, that get add leftover also and QX, some were of The the to shoes understand I patients of,

So it XXX. than know that are where patients like they seems less

to seems bit last than quarter. seems a to it little there be So less be,

was So should cadence patients, exact just how think forward? what trying we denoble a Thank for to [ph] about you. and the going get number sense,

Stephen Farr

us. can new patients. question the XXX your take second novo And this patients. are I for with There de the respect actually just of to on cadence first,

reimburse patients by want you do the the the quarter. around patients to already program, to this And what reimburse were this them the on and went are end REMS last Early and year. so in of remainder about in final of So last XX% the already treatment Access in treatment on know

count ramp reps. in into to respect this new already I they're through continue think to not we as quarter. Mark expect don't earlier. saw reiterate the mass with they And The the muscle QX, so cadence, saw patients in will that's I However, we increase against overall just coming what and that patients go the said the we number in rate we of I've

the was million in States total XX.X sales of On Europe. United and million in that sales, a net XX.X servers million of

Yatin Suneja

maybe Got launch it. patient early And patients in compliance very then rate? the I And the you're the per discontinuation color drug it's seeing rate comment on can average what that or the on if understand you any for

Stephen Farr

to you question. address ask will I that Ashish,

Ashish Sagrolikar

weight. start average Yes, with the I'll

XX is expanded average are consistent So we what the we the saw in that kilogram. access program seeing in around

XX% around the there. rate So average as point compliance, remarks, the in And the I the right get XX. persistence who started expanded my well trials, around you it's patients early, range said the access, in said, as prepared as clinical really so but on is XX%, discontinuations again, this But therapy. And still of the the XX%. time, that the at they're percent in is now I

we and and that I right there. are But product. great seeing the will great results, they're benefiting, think results. So are a seeing get Patients expect then we we on now, staying they're

Yatin Suneja

Thank you very much.

Operator

[ph] Meena Please question with ahead. last of The go the from Citi. comes line

Unidentified Analyst

this thanks have patients who guys, guess on months. some taking monitoring. for for around six I have And, been cardiac commercial Hey, question the point, question. you at The know, drug my you

Is guess. of? their proving the any smooth that has eco? that kind kind would of getting that they for months going months. to baseline I six going? the been echoes as of there proving in be as for kind be Has in essentially patients of to Or be echo, terms now issues How Kind been of been six going? have is Thanks. So

Ashish Sagrolikar

I think exactly smooth. cardiac the it's And it monitoring. as you does serve the going ecos been second goes that said,

patients, know have physicians. lot version connected and really you individual’s as We top records expanded the know, stays that in which months. know on to of extension of the as know, any stay of therapy, back you on patients program, we six haven't some we reminds And really past time And and already we families went commercial the the a who with a the many robust it, And had have patients some patients they that. clinical had the trial there. access, challenges

again, we So get in lot to have been challenges. of one gone any of went have through it able we a who cause, since even without patients the and time have secondary every year, and last them

Unidentified Analyst

Thanks. I And then one on. if Perfect. question I guess more could ask just quickly, Gotcha.

kind Just kind commercial think, patients of the of you of were new in going of thinking that drug, patients to number the start I yet about number of of pace were the the kind rather know, on to starts, that than back rooms.

fourth starts or in are new closer quarter, I the it XXX and in quarter, this it's quintuple seems there you naive, think I XXX. calculated, know, to so fourth like about quarter

said, patients from there pace over number have some month starts what's number new there of, understanding think like of EAP guys of new over starting [ph]. the here we increase? Just that I about month in guess, orally is should starts a drugs go know, where But were still this from could you terms how couple the given that mean, Thanks. reasonable the I that, quarters? you of next OLE

Ashish Sagrolikar

Yep.

answer consistent move giving saw, we not XXX as quarter. as have seen we that be we the any see guidance. into continue a And But we the in earlier, will Steve an we said, to So increase second month that month. over

as have any or terms So And coming from that from guidance, well patients did if I program in QX, as expanded trial would will. were you we access if in. for the not the be think the clinical of you one QX, in

I XXX every going to earlier, be So everyone new to growth and FINTEPLA. that FINTEPLA from that that's saw going around us said that to you new to for patients is come

Stephen Farr

Yeah, so add I'll color. a just little

them taking that are to QX, are four referred I sure getting pretty familiar a new takes there programs the we And and much and as program. and holding basically through in the XXX where impact program drugged is with get point, the the through level and whatnot. patients the holidays set starts of finished recent the we the starts screen, and with, getting COVID the they've payer in In weeks, which covered severe in to I'm had coming close REMS the you're in QX, set January up been the this year, just pretty January So of three, same, total dry, XXX% we restarting through being at big to the new are then people pandemic, off had and between about through impact number. XXX. are function XXX And think and it's same around roughly of the initial new to coming elements to referred other and that it's although

to increasing this quarter increasing January with increases and this as starting, throughout also month saw had and and you typical keeping then well. into So your quarter we up month

know expect come that to you by for the able of were start to so we and maintain of it And it capacity to also to demand the through because increasing balance quarter January increase year quarters that was were to the end by challenge to great this be COVID. the for to So through be and you impact the less that we the pace the lower time quarter. on what quarter of the getting and it lower see is standardly

Unidentified Analyst

Thank you.

Operator

line, over questions further phone on the I'll No turn back call the you. to

Stephen Farr

and you much operator today. to very you joining all for Thank our thanks call of

and treatment will patients critical be quarter our needs. the focus commercial call past programs for incredibly unmet This new continue has been to advancing options us we serious clinical active for [indiscernible] bring like to facing on medical

to you again So further now. guiding day. a updates with call rest on of enjoy joining this the I throughout Thank activities today year. really for and Bye us your you look all and forward

Operator

your lines. you disconnect That thank does and ask the participation for conference conclude you call for please today. We your

Zogenix (ZGNX) 7 May 212021 Q1 Earnings call transcript